Skip to content
PEPLUX

Kisspeptin-10 peptide

Kisspeptin Injection

Also called Kisspeptin, KP-10.

Illustrative PEPLUX product vial in a purple-lit studio
Product illustration

Product form

Subcutaneous injection

The process

Licensed provider review

Kisspeptin Injection cost

$229 per month

*If medically eligible.
Medication
Included
Clinician visit
Included
Baseline labs
Included
Lab retests
Included when ordered by your provider
Shipping
Included
Patient portal access
Included
Care-team chat support
Included

Considering more than one product?

  • Two products prescribed together: $349 per month
  • Three products prescribed together: $479 per month
Compare pricing

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

FDA status, checked on October 14, 2026

Kisspeptin Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.

Prescription products require an online evaluation with a licensed provider. Not all patients qualify.

States served: not yet confirmed. How state availability works

What is Kisspeptin Injection?

This listing refers to kisspeptin-10. Other kisspeptin forms are different substances. The dispensing pharmacy must confirm the peptide identity and formulation before ordering is enabled.

Adults seeking a provider discussion about kisspeptin-10 after reviewing its evidence limitations and risks. The request should be assessed in the context of a medical history and established care options.

Key risks

  • Safety information for kisspeptin-10 is limited. Side effects and longer-term risks of this formulation have not been adequately established.
  • Peptide-related immune reactions and impurities are safety concerns. Prior allergic or immune reactions require review.
All risks and who should not use it

FDA status

FDA status for Kisspeptin Injection.

Rendered from our regulatory records, which cite FDA, Federal Register and label documents directly. Each record shows the date we last checked it.

No compounding pathway today.

Kisspeptin Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Kisspeptin Injection

No compounding pathway today.

FDA’s documents list it as Kisspeptin-10.

Kisspeptin-10 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. It remains in FDA's 503A Category 2 for substances that may present significant safety risks. FDA's Pharmacy Compounding Advisory Committee voted against placing it on the 503A bulks list on October 29, 2024.

This record covers kisspeptin-10. Kisspeptin-54 is a different form and is not covered by this record.

Basis
FDA's current 503A categories document lists kisspeptin-10 in Category 2. Its October 2024 evaluation states that there is no applicable USP or NF drug-substance monograph and it is not a component of an FDA-approved drug. It is not on the 503A or 503B bulks list. The advisory committee's final minutes record a vote against its inclusion. FDA identifies potential immune reactions, peptide impurities and limited safety information as concerns.
Checked on
October 14, 2026

How it works

Kisspeptin Injection mechanism.

Kisspeptin-10 is a short form of kisspeptin. It is distinct from kisspeptin-54, and information about one form must not be assumed to describe the other. The exact peptide identity and formulation require confirmation by the prescriber and pharmacy.

That describes what the molecule does in the body. It is not a claim about what it will do for you.

What the evidence supports

Kisspeptin Injection: evidence and limitations.

Research findings do not establish a safe and effective regimen for this product. Safety information is limited, and a product listing does not establish a clinical benefit or justify replacing an established treatment.

Risks

Kisspeptin Injection risks and side effects.

  • Safety information for kisspeptin-10 is limited. Side effects and longer-term risks of this formulation have not been adequately established.
  • Peptide-related immune reactions and impurities are safety concerns. Prior allergic or immune reactions require review.
  • Injection can cause pain, redness, swelling or bruising. Infection is possible if the product or injection technique is not sterile.
  • Safety information is insufficient for use during pregnancy or breastfeeding or in people under 18. These groups should not use this product.
  • Seek urgent medical care for trouble breathing, swelling of the face or throat, or other signs of a serious allergic reaction.

This information is educational and is not medical advice. It does not establish a provider–patient relationship.

Clinical review

What your prescriber will consider.

These are decision factors a licensed provider weighs when deciding whether this product is appropriate for you. They are not instructions, and there is no dosing protocol on this page.

  • Confirmation that the ingredient is kisspeptin-10 rather than a different kisspeptin form

  • Medical history, current hormone treatment and other prescription medicines or supplements

  • The reason for seeking treatment and whether established evaluation or treatment should come first

  • Pregnancy, breastfeeding, plans to conceive and any applicable anti-doping rules

PEPLUX does not publish self-administration protocols. Dose, frequency and duration are set by your prescriber against your own history and reviewed over time.

Lot documents

What a certificate of analysis should cover.

When a pharmacy is named, each lot's certificate of analysis is expected to cover the tests below. No certificate exists or is published yet.

  • Potency
  • Sterility
  • Endotoxin
  • pH

Sport and anti-doping

Prohibited under the WADA code.

  • Prohibited at all times in males under WADA class S2.2.1 (testosterone-stimulating peptides). The 2026 list names kisspeptin and its agonist analogues under testosterone-stimulating peptides in males.

If you compete under an anti-doping authority, or are tested through your employer or federation, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.

Straight answers

Common questions about Kisspeptin Injection.

What is the FDA status of Kisspeptin Injection?
No compounding pathway today. Kisspeptin-10 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. It remains in FDA's 503A Category 2 for substances that may present significant safety risks. FDA's Pharmacy Compounding Advisory Committee voted against placing it on the 503A bulks list on October 29, 2024. Checked against primary sources on October 14, 2026.
Is compounded Kisspeptin Injection an approved drug?
No. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. Kisspeptin Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established. PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.
What does the evidence support for Kisspeptin Injection, and what does it not?
Research findings do not establish a safe and effective regimen for this product. Safety information is limited, and a product listing does not establish a clinical benefit or justify replacing an established treatment.
What are the risks of Kisspeptin Injection?
Safety information for kisspeptin-10 is limited. Side effects and longer-term risks of this formulation have not been adequately established. The full list of side effects, and of who should not use Kisspeptin Injection, is in the risks section of this page. Your prescriber reviews your history before deciding whether it is appropriate for you.
Does Kisspeptin Injection require baseline labs?
Your prescriber determines whether baseline labs are needed before considering Kisspeptin Injection. Baseline labs are included in the price.
What does Kisspeptin Injection cost?
$229 per month. Medication: included. Clinician visit: included. Baseline labs: included. Lab retests: included when ordered by your provider. Shipping: included. Patient portal access: included. Care-team chat support: included. *If medically eligible.
Is Kisspeptin Injection prohibited in sport?
Prohibited at all times in males under WADA class S2.2.1 (testosterone-stimulating peptides). The 2026 list names kisspeptin and its agonist analogues under testosterone-stimulating peptides in males. If you are subject to anti-doping testing, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.
How is Kisspeptin Injection given?
Subcutaneous injection. Your prescriber decides whether it is appropriate for you and sets the regimen. PEPLUX does not publish dosing.

Next step

A licensed provider reviews every request.

Kisspeptin Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Also offered

Other products.

All productsFDA status tracker